Duke Floats Ways To Collect Alzheimer’s Data Without Cutting Drug Access

By Jessica Karins / June 2, 2023 at 1:06 PM
As CMS cements its plan to hinge broad coverage of Alzheimer’s anti-amyloid drugs that are fully approved by FDA on patients participating in registries, prominent health policy researchers are warning CMS to tread carefully because the registry requirement could cut off treatments for patients whose providers have limited capacity to collect data and may not be able to safely administer the drugs. The researchers lay out ways CMS could still collect post-market data while maximizing access to treatments. Duke Margolis...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.